- Home
- MCRB vs ELTX Comparison
MCRB vs ELTX Comparison
Compare MCRB & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- ELTX
- Stock Information
- Founded
- MCRB 2010
- ELTX 2011
- Country
- MCRB United States
- ELTX United States
- Employees
- MCRB N/A
- ELTX N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- ELTX Health Care
- Exchange
- MCRB Nasdaq
- ELTX Nasdaq
- Market Cap
- MCRB 144.8M
- ELTX 158.5M
- IPO Year
- MCRB 2015
- ELTX N/A
- Fundamental
- Price
- MCRB $16.87
- ELTX $8.77
- Analyst Decision
- MCRB Hold
- ELTX Strong Buy
- Analyst Count
- MCRB 3
- ELTX 1
- Target Price
- MCRB $14.33
- ELTX $13.00
- AVG Volume (30 Days)
- MCRB 88.5K
- ELTX 104.1K
- Earning Date
- MCRB 11-05-2025
- ELTX 11-13-2025
- Dividend Yield
- MCRB N/A
- ELTX N/A
- EPS Growth
- MCRB N/A
- ELTX N/A
- EPS
- MCRB 0.62
- ELTX N/A
- Revenue
- MCRB $351,000.00
- ELTX N/A
- Revenue This Year
- MCRB N/A
- ELTX N/A
- Revenue Next Year
- MCRB N/A
- ELTX N/A
- P/E Ratio
- MCRB $26.91
- ELTX N/A
- Revenue Growth
- MCRB N/A
- ELTX N/A
- 52 Week Low
- MCRB $6.53
- ELTX $4.60
- 52 Week High
- MCRB $24.67
- ELTX $12.62
- Technical
- Relative Strength Index (RSI)
- MCRB 51.80
- ELTX 34.58
- Support Level
- MCRB $12.48
- ELTX $8.60
- Resistance Level
- MCRB $14.35
- ELTX $9.49
- Average True Range (ATR)
- MCRB 1.18
- ELTX 0.49
- MACD
- MCRB 0.22
- ELTX 0.02
- Stochastic Oscillator
- MCRB 80.50
- ELTX 14.10
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.